Triple therapy for advanced colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs—tislelizumab (an immunotherapy), fruquintinib (a targeted therapy), and chidamide (a drug that may help immune cells fight cancer)—in people with colorectal cancer that has spread to the liver and hasn't responded to standard chemotherapy. The goal is to see if this triple combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to your liver and can't be removed by surgery.
- You have already tried chemotherapy with fluorouracil, oxaliplatin, and irinotecan, and it either didn't work or caused bad side effects.
- Your tumor is MSS or pMMR (a type of colorectal cancer that is stable, not highly mutated).
- Your doctor has confirmed that your blood counts, kidney, and liver function are good enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
This trial tests a combination of two oral drugs (fruquintinib and camrelizumab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with advanced colorectal cancer that has spread to the liver. It's for those whose first treatment has stopped working and whose cancer is not the MSI-H type.
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.